ATE481971T1 - Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung - Google Patents

Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung

Info

Publication number: ATE481971T1
Authority: AT; Austria
Prior art keywords: piperazinyl; amino; release formulation; sustained release; disorders
Prior art date: 2004-07-15

Application number

AT05761109T

Other languages

English (en)

Inventor

Nico Bruins

Henderik W Frijlink

Vries Michiel H De

Original Assignee

Abbott Healthcare Products Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-15

Filing date

2005-07-13

Publication date

2010-10-15

2005-07-13 Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE481971T1 publication Critical patent/ATE481971T1/de

Links

238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
AHWHLBJKIFHNIV-UHFFFAOYSA-N 3-amino-8-piperazin-1-ylchromen-2-one Chemical compound C=12OC(=O)C(N)=CC2=CC=CC=1N1CCNCC1 AHWHLBJKIFHNIV-UHFFFAOYSA-N 0.000 title abstract 2
238000013268 sustained release Methods 0.000 title 1
239000012730 sustained-release form Substances 0.000 title 1
238000013265 extended release Methods 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000016285 Movement disease Diseases 0.000 abstract 1
208000027520 Somatoform disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000027753 pain disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrane Compounds (AREA)

AT05761109T 2004-07-15 2005-07-13 Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung ATE481971T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US58803604P	2004-07-15	2004-07-15
EP04103378		2004-07-15
PCT/EP2005/053341 WO2006005760A1 (en)	2004-07-15	2005-07-13	Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one

Publications (1)

Publication Number	Publication Date
ATE481971T1 true ATE481971T1 (de)	2010-10-15

Family

ID=34978928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05761109T ATE481971T1 (de)	2004-07-15	2005-07-13	Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung

Country Status (8)

Country	Link
EP (1)	EP1781292B1 (de)
JP (1)	JP2008506668A (de)
AT (1)	ATE481971T1 (de)
CA (1)	CA2570096A1 (de)
DE (1)	DE602005023742D1 (de)
PL (1)	PL1781292T3 (de)
PT (1)	PT1781292E (de)
WO (1)	WO2006005760A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8497258B2 (en)	2005-11-12	2013-07-30	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2765033C (en)	2009-06-12	2020-07-14	Meritage Pharma, Inc.	Methods for treating gastrointestinal disorders
EP2468264A1 (de) *	2010-12-27	2012-06-27	Laboratorios Liconsa, S.A.	Orale pharmazeutische Tablette zur gesteuerten Abgabe von Mesalazin und Verfahren zu deren Erhalt
GB201504986D0 (en) *	2015-02-13	2015-05-06	Johnson Matthey Plc	Oxidation catalyst for treating a natural gas emission
JP6983139B2 (ja) *	2017-11-27	2021-12-17	信越化学工業株式会社	固形製剤用組成物並びに固形製剤及びその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0650964A1 (de) *	1993-11-02	1995-05-03	Duphar International Research B.V	1- 2H-1-Benzopyran-2-on-8-yl -Piperazin Derivate
US5478572A (en) *	1994-09-06	1995-12-26	Bristol-Myers Squibb Co.	Gepirone dosage form
NL9401572A (nl) *	1994-09-27	1996-05-01	Avebe Coop Verkoop Prod	Zetmeelprodukten als tabletteerhulpstof, werkwijze voor het bereiden daarvan alsmede werkwijze voor het maken van tabletten.
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
US6312717B1 (en) *	1998-07-07	2001-11-06	Bristol-Myers Squibb Company	Method for treatment of anxiety and depression

2005
- 2005-07-13 AT AT05761109T patent/ATE481971T1/de active
- 2005-07-13 JP JP2007520835A patent/JP2008506668A/ja active Pending
- 2005-07-13 WO PCT/EP2005/053341 patent/WO2006005760A1/en not_active Ceased
- 2005-07-13 PL PL05761109T patent/PL1781292T3/pl unknown
- 2005-07-13 PT PT05761109T patent/PT1781292E/pt unknown
- 2005-07-13 EP EP05761109A patent/EP1781292B1/de not_active Expired - Lifetime
- 2005-07-13 CA CA002570096A patent/CA2570096A1/en not_active Abandoned
- 2005-07-13 DE DE602005023742T patent/DE602005023742D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1781292A1 (de)	2007-05-09
JP2008506668A (ja)	2008-03-06
PL1781292T3 (pl)	2011-03-31
DE602005023742D1 (de)	2010-11-04
CA2570096A1 (en)	2006-01-19
WO2006005760A1 (en)	2006-01-19
EP1781292B1 (de)	2010-09-22
PT1781292E (pt)	2010-12-23

Similar Documents

Publication	Publication Date	Title
EA202091303A2 (ru)	2021-03-31	Композиция ингибитора jak для местного применения
BR0312573A (pt)	2005-04-26	Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
WO2006096434A3 (en)	2007-03-29	Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
ATE530544T1 (de)	2011-11-15	Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
DOP2002000429A (es)	2003-10-15	Imidazotriazinas
TNSN07376A1 (en)	2009-03-17	Npy antagonists, preparation and use
ATE466580T1 (de)	2010-05-15	Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de)	2010-06-15	Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de)	2007-07-15	Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60223254D1 (de)	2007-12-13	Verzögert freisetzende formulierungen von oxymorphon
SG146657A1 (en)	2008-10-30	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE602006015851D1 (de)	2010-09-09	Positive allosterische chinolon-m1-rezeptormodulatoren
NO20072558L (no)	2007-07-18	Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
DK1556021T3 (da)	2008-04-28	Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
CY1105082T1 (el)	2010-03-03	Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
BRPI0407662B8 (pt)	2021-05-25	derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
UA90858C2 (ru)	2010-06-10	Композиция с контролируемым высвобождением варденафила
MY142329A (en)	2010-11-15	Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
ATE453642T1 (de)	2010-01-15	Substituierte phenylaminopyrimidine
MXPA05004247A (es)	2005-10-18	Cromonas y derivados de cromona y usos de los mismos.
UA92000C2 (en)	2010-09-27	1-benzylindole-2-carboxamide derivatives
ATE448232T1 (de)	2009-11-15	Substituierte heterozyklen
CO5660287A2 (es)	2006-07-31	Derivados de tetrahidrocarbazol y su uso farmaceutico
ATE481971T1 (de)	2010-10-15	Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung

Legal Events

Date

Code

Title

Description

2011-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1781292

Country of ref document: EP